3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Warts
2
Virus Diseases
1
Skin Diseases, Viral
1
Skin Diseases, Infectious
1
Skin Diseases
1
Sexually Transmitted Diseases, Viral
1
Sexually Transmitted Diseases
1
Papillomavirus Infections
1
Condylomata Acuminata
1
Interventions
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
14
Vaccines, Synthetic
10
Papillomavirus Vaccines
6
Vaccines
5
Imiquimod
4
Trichloroacetic Acid
3
Gels
3
green tea extract polyphenone E
2
Podophyllin
2
Human Papillomavirus Recombinant Vaccine nonavalent
2
Ethanol
2
Duration of Therapy
2
Cryotherapy
2
Cantharidin
2
ranpirnase
1
polyphenon E
1
nanocurcumin
1
human papillomavirus vaccine, L1 type 16, 18
1
hecolin
1
berdazimer sodium
1
Zinc
1
Viusid
1
Vaccination
1
VP-102
1
Tuberculin
1
Therapies, Investigational
1
Tea
1
PRA1 protein, Candida albicans
1
Omiganan
1
Ointments
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Condylomata Acuminata
×
VP-102
×
Clear all
NCT03981822
2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2
Completed
105 enrolled
24 charts